- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- Three new Takeda diabetes drugs become available
- BD launches needle aimed at diabetics
- Study: Type 2 diabetes market competition heats up amid disease rate increase
- FDA advisory committee recommends approval for Bristol-Myers Squibb's, AstraZeneca's metreleptin in generalized lipodystrophy
PRINCETON, N.J. — A new oral treatment for Type 2 diabetes hit the shelves Friday.
Bristol-Myers Squibb and AstraZeneca announced the availability of Kombiglyze XR (saxagliptin and metformin hydrochloride), which the companies called the only once-daily treatment for diabetes that combined metformin with a DPP-4 inhibitor, the drug class to which saxagliptin belongs.
The drug is designed for use alongside diet and exercise to improve glycemic control in adults with Type 2 diabetes.